Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Trikafta in Cystic Fibrosis (F/G and F/RF Genotypes)
NCT04058366Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Dec 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of elexacaftor + tezacaftor + ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Dec 2019; status: completed.
02
Drugs
elexacaftor + tezacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04058366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04058366.